Research programme: antibacterial therapeutics - Gunsynd

Drug Profile

Research programme: antibacterial therapeutics - Gunsynd

Alternative Names: SYN 0017; SYN 0096; SYN 0854; SYN 101; SYN 102; SYN 1093; SYN 1163

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntopix
  • Developer Gunsynd
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne; Staphylococcal infections

Highest Development Phases

  • No development reported Acne; Mouth disorders; Staphylococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acne in United Kingdom (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mouth-disorders in United Kingdom (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top